Few data are available on the management of critically ill pregnant women with pneumonia related to SARS-CoV-2. In the absence of clear recommendations for the management of delivery, clinicians are faced with the risk of pregnancy continuation against the risk of premature birth. In these multicenter retrospective study, the investigators want to describe clinicians attitude on delivery management in pregnant women requiring invasive mechanical ventilation for acute respiratory distress syndrome related to SARS-CoV-2. Two strategies will be compared on maternal, obstetric and neonatal outcomes: * Wait strategy defined by no extraction within 24 hours of invasive venting * Early strategy defined by extraction within 24 hours of invasive ventin
Study Type
OBSERVATIONAL
Enrollment
100
No intervention
40 Avenue de Verdun
Créteil, France
Compare two fetal extraction strategies: - Wait strategy defined by no extraction within 24 hours of invasive venting - Early strategy defined by extraction within 24 hours of invasive venting
Assessment Criterion 1: Maternal prognosis assessed by: * Mortality * Duration of invasive mechanical ventilation * Need for ECMO * Use of prone position and/or nitric oxide and/or almitrine * Adverse events: cardiac arrest, organ failure, thromboembolic episodes, nosocomial infections, barotrauma * Length of stay in the ICU and in the hospital Assessment Criterion 2: Obstetric prognosis assessed by: * Fetal extraction in the ICU room due to a contraindication to transport (maternal and/or fetal risk) * Delivery route * Peri partum hemorrhage * Complications of obstetric anesthesias Assessment Criterion #3: Fetal Prognosis Assessed by: * Term birth, * Weight, * Apgar, * pH cord blood, * Need for ICU admission, * Death
Time frame: 'Day 1.
Number of patient requiring invasive mechanical ventilation with or without ECMO
Number of patient requiring invasive mechanical ventilation with or without ECMO
Time frame: 'Day 1.
Number of patients receiving pharmacological treatments for the management of COVID: corticosteroids, antivirals, anti-IL6, anticoagulants, antibiotics
Number of patients receiving pharmacological treatments for the management of COVID: corticosteroids, antivirals, anti-IL6, anticoagulants, antibiotics
Time frame: Day 1.
Evolution over time of the number of patients admitted to the ICU in the participating
Evolution over time of the number of patients admitted to the ICU in the participating centers (1st, 2nd, 3rd epidemic wave)
Time frame: Day 1.
Evolution over time of the number of patients admitted to the ICU in the participating
Evolution over time of the number of patients admitted to the ICU in the participating
Time frame: Day 1.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.